Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vebicorvir
- Development stage
- Discontinued
- Lead developer
- Assembly Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vebicorvir is a first-generation, orally available small molecule that acts as a hepatitis B virus (HBV) core protein inhibitor. It was developed to treat chronic HBV infection by targeting the viral core protein, thereby preventing encapsidation of pregenomic RNA and subsequent DNA replication. Vebicorvir suppresses covalently closed circular DNA (cccDNA) formation and has demonstrated effective antiviral activity in clinical studies. Its mechanism of action is orthogonal to standard-of-care nucleos(t)ide reverse transcriptase inhibitors (NrtIs), and it has been studied in combination with these agents for enhanced suppression of HBV[1][2][4][5][8]. The drug was primarily developed by Assembly Biosciences and Antios Therapeutics but its development for hepatitis B has been discontinued[4].
- Other names
- vebicorvir
02
Targets
HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on vebicorvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vebicorvir.